News
Real-world study counts hyperprogression after checkpoint inhibitors in routine practice
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A retrospective study across four French cancer centres, published in Cancer Communications on 17 June 2026, looked for hyperprogressive disease in routine practice among 13,250 patients with solid tumours who received at least one immune checkpoint inhibitor. Clinicians’ notes mentioned hyperprogression in 0.43% of patients (57 cases, with a range of 0.16% to 0.89% between centres); the most common primary cancers were lung (36.8%), kidney (14.0%) and head and neck (14.0%). The authors write that definitions of hyperprogression still differ between studies, which complicates recognition in routine practice and decisions about continuing or stopping immunotherapy.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open-access article (CC BY 4.0); the link goes to the PubMed record because the publisher site blocks automated access (dev-083). Our own summary, no full-text copy.